IP Library Granted Patent US 9,249,095
Granted Patent B2
US 9,249,095 · App. 14/125,597 · Granted Feb 2, 2016

2-methylthiopyrrolidines and their use for modulating bacterial quorum sensing

Inventors: Venkata L. Malladi (Cranberry Township, PA); Lisa Schneper (Lititz, PA); Adam J. Sobczak (Easley, SC); Kalai Mathee (Miami, FL); Stanislaw F. Wnuk (Miami, FL)
Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
C07D207/273A61K31/40A61K31/4025C07D207/12C07D207/267
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,249,095
App. No.
14/125,597
Granted
Feb 2, 2016
Kind
B2
Abstract

Compounds of Formula (I) are disclosed herein and their use in inhibiting quorum sensing in bacteria.

Claims (16)

1. A compound having a structure selected from

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

3. A method of inhibiting bacterial quorum sensing comprising contacting bacteria with the compound of claim 1 .

4. The method of claim 3 , wherein the bacteria is selected from the group consisting of : Acinetobacter baumannii, Aeromonas hydrophila, Aeromonas salmonicida, Agrobacterium tumefaciens, Brucella melitensis, Burkholderia cenocepacia, Burkholderia mallei, Burkholderia pseudomallei, Burkholderia vietnamiensis, Chromobacterium violaceum, Enterobacter agglomeran, Erwinia carotovora, Erwinia chrysanthemi, Escherichia coli, Nitrosomas europaea, Obesumbacterium proteus, Pantoea agglomerans, Pantoea stewartii, Pseudomonas aureofaciens, Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas fuscovaginae, Pseudomonas syringae, Ralstonia solanacearum, Rhizobium etli, Rhizobium leguminosarum, Rhodobacter sphaeroides, Serratia liquefaciens, Serratia marcescens, Vibrio anguillarum, Vibrio fischeri, Vibrio parahaemolyticus, Vibrio salmonicida, Xanthomonas campestris, Xenorhabdus nematophilus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia medievalis, Yersinia ruckeri , and combinations thereof.

5. The method of claim 3 , wherein the contacting comprises administering the compound or the composition to a subject suffering from a bacterial infection.

6. The method of claim 5 , further comprising administering a second agent to the subject.

7. The method of claim 6 , wherein the second agent is an antibiotic.

8. The method of claim 7 , wherein the antibiotic is selected from a penicillin, a selexcid, a cephalosporin, a tetracycline, a rifamycin, gentamycin, clindamycin, a fluoroquinolone, a monobactamer, a carbapeneme, a macrolide, a polymyxin, an aminoglycoside, tobramycin, a sulfonamide, a fusidine, a vancomycin, an oxazolidinone, a metronidazole, a corticosteroid, hydrocortisone, triamcinolone, betamethasone, and combinations thereof.

9. A method of treating a subject suffering from an infection comprising administering to the subject an effective amount of the compound of claim 1 .

10. The method of claim 9 , further comprising administering to the subject a second therapeutic.

11. The method of claim 10 , wherein the second therapeutic is an antibiotic.

12. The method of claim 11 , wherein the antibiotic is selected from a penicillin, a selexcid, a cephalosporin, a tetracycline, a rifamycin, gentamycin, clindamycin, a fluoroquinolone, a monobactamer, a carbapeneme, a macrolide, a polymyxin, an aminoglycoside, tobramycin, a sulfonamide, a fusidine, a vancomycin, an oxazolidinone, a metronidazole, a corticosteroid, hydrocortisone, triamcinolone, betamethasone, and combinations thereof.

13. The method of claim 9 , wherein the infection is a P. aeruginosa infection.

14. A method of inhibiting formation of a biofilm comprising contacting bacteria the compound of claim 1 .

15. The method of claim 14 , wherein the contacting comprises administering the compound or the composition to a subject suffering from a bacterial infection.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2014
From: MALLADI, VENKATA L.; SCHNEPER, LISA; SOBCZAK, ADAM J.; MATHEE, KALAI; WNUK, STANISLAW F.
To: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
Reel/Frame 033131/0030 →
Continuity (2)
Provisional Application 61497811 · Jun 16, 2011
Related Publication 20140128446A1 · May 8, 2014